Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,18397687,tmax,"In addition, the median tmax values for the test and reference formulations were similar (5.00 h).",Comparative bioavailability of two sertraline tablet formulations after single-dose administration in healthy Thai volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397687/),h,5.00,5289,DB01104,Sertraline
,15497672,Cmax,"The mean Cmax were 9.01 +/- 2.26 ng/mL and 8.24 +/- 2.14 ng/mL, while the mean AUC0-t were 259.09 +/- 105.36 ng x h/mL and 234.36 +/- 95.18 ng x h/mL for the test and reference formulations, respectively.",Serotonin reuptake inhibitors: bioequivalence of sertraline capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497672/),[ng] / [ml],9.01,7922,DB01104,Sertraline
,15497672,Cmax,"The mean Cmax were 9.01 +/- 2.26 ng/mL and 8.24 +/- 2.14 ng/mL, while the mean AUC0-t were 259.09 +/- 105.36 ng x h/mL and 234.36 +/- 95.18 ng x h/mL for the test and reference formulations, respectively.",Serotonin reuptake inhibitors: bioequivalence of sertraline capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497672/),[ng] / [ml],8.24,7923,DB01104,Sertraline
,15497672,AUC0-t,"The mean Cmax were 9.01 +/- 2.26 ng/mL and 8.24 +/- 2.14 ng/mL, while the mean AUC0-t were 259.09 +/- 105.36 ng x h/mL and 234.36 +/- 95.18 ng x h/mL for the test and reference formulations, respectively.",Serotonin reuptake inhibitors: bioequivalence of sertraline capsules. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497672/),[h·ng] / [ml],259.09,7924,DB01104,Sertraline
,15497672,AUC0-t,"The mean Cmax were 9.01 +/- 2.26 ng/mL and 8.24 +/- 2.14 ng/mL, while the mean AUC0-t were 259.09 +/- 105.36 ng x h/mL and 234.36 +/- 95.18 ng x h/mL for the test and reference formulations, respectively.",Serotonin reuptake inhibitors: bioequivalence of sertraline capsules. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497672/),[h·ng] / [ml],234.36,7925,DB01104,Sertraline
,15497672,AUC0-inf,The mean AUC0-inf were 292.66 +/- 128.09 ng x h/mL (test) and 267.23 +/- 116.40 ng x h/ mL (reference).,Serotonin reuptake inhibitors: bioequivalence of sertraline capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497672/),[h·ng] / [ml],292.66,7926,DB01104,Sertraline
,15497672,AUC0-inf,The mean AUC0-inf were 292.66 +/- 128.09 ng x h/mL (test) and 267.23 +/- 116.40 ng x h/ mL (reference).,Serotonin reuptake inhibitors: bioequivalence of sertraline capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497672/),[h·ng] / [ml],267.23,7927,DB01104,Sertraline
,15497672,tmax,The mean tmax was 5.88 +/- 1.03 h for the test capsules and 6.17 +/- 1.66 h for the reference formula.,Serotonin reuptake inhibitors: bioequivalence of sertraline capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497672/),h,5.88,7928,DB01104,Sertraline
,15497672,tmax,The mean tmax was 5.88 +/- 1.03 h for the test capsules and 6.17 +/- 1.66 h for the reference formula.,Serotonin reuptake inhibitors: bioequivalence of sertraline capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497672/),h,6.17,7929,DB01104,Sertraline
,15497672,t1/2el,The mean t1/2el was 26.49 +/- 6.45 h for the test formulation and 26.23 +/- 6.64 h for the reference formulation.,Serotonin reuptake inhibitors: bioequivalence of sertraline capsules. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497672/),h,26.49,7930,DB01104,Sertraline
,15497672,t1/2el,The mean t1/2el was 26.49 +/- 6.45 h for the test formulation and 26.23 +/- 6.64 h for the reference formulation.,Serotonin reuptake inhibitors: bioequivalence of sertraline capsules. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497672/),h,26.23,7931,DB01104,Sertraline
,15497672,MRT,"Mean MRT values for the test and reference formulations were 28.14 +/- 5.37 h and 27.81 +/- 5.13 h, respectively.",Serotonin reuptake inhibitors: bioequivalence of sertraline capsules. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497672/),h,28.14,7932,DB01104,Sertraline
,15497672,MRT,"Mean MRT values for the test and reference formulations were 28.14 +/- 5.37 h and 27.81 +/- 5.13 h, respectively.",Serotonin reuptake inhibitors: bioequivalence of sertraline capsules. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497672/),h,27.81,7933,DB01104,Sertraline
,10598311,half-life,"The half-life of fluoxetine and its active metabolite norfluoxetine is respectively 2 to 4 days and 7 to 15 days, more extended than other SSRIs (approximately 1 day).",[Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598311/),d,2 to 4,14164,DB01104,Sertraline
,10598311,half-life,"The half-life of fluoxetine and its active metabolite norfluoxetine is respectively 2 to 4 days and 7 to 15 days, more extended than other SSRIs (approximately 1 day).",[Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598311/),d,7 to 15,14165,DB01104,Sertraline
,10598311,half-life,"The half-life of fluoxetine and its active metabolite norfluoxetine is respectively 2 to 4 days and 7 to 15 days, more extended than other SSRIs (approximately 1 day).",[Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598311/),d,1,14166,DB01104,Sertraline
,9068932,t1/2 beta,"The terminal elimination half-life (t1/2 beta ) of sertraline was similar in young females, elderly males and elderly females (mean t1/2 beta ranged from 32.1 to 36.7 hours in these groups) but shorter (22.4 hours) in the young males.",Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068932/),h,32.1 to 36.7,15861,DB01104,Sertraline
,9068932,t1/2 beta,"The terminal elimination half-life (t1/2 beta ) of sertraline was similar in young females, elderly males and elderly females (mean t1/2 beta ranged from 32.1 to 36.7 hours in these groups) but shorter (22.4 hours) in the young males.",Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068932/),h,22.4,15862,DB01104,Sertraline
,9068932,time to Cmax,The time to Cmax was unaffected by age or gender and ranged from 6.4 to 6.9 hours.,Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068932/),h,6.4 to 6.9,15863,DB01104,Sertraline
,30788337,dose-normalized AUC 0-24,"Sertraline exposure was highest for HIV(-) and lowest for EFV cohorts; median dose-normalized AUC 0-24 was 1176 (HIV(-)), 791 (PI/r) and 473 (EFV) ng*hr/mL, and C24 was 32.7 (HIV(-)), 20.1 (PI/r), and 12.8 (EFV) ng/mL.","Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30788337/),[h·ng] / [ml],1176,25165,DB01104,Sertraline
,30788337,dose-normalized AUC 0-24,"Sertraline exposure was highest for HIV(-) and lowest for EFV cohorts; median dose-normalized AUC 0-24 was 1176 (HIV(-)), 791 (PI/r) and 473 (EFV) ng*hr/mL, and C24 was 32.7 (HIV(-)), 20.1 (PI/r), and 12.8 (EFV) ng/mL.","Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30788337/),[h·ng] / [ml],791,25166,DB01104,Sertraline
,30788337,dose-normalized AUC 0-24,"Sertraline exposure was highest for HIV(-) and lowest for EFV cohorts; median dose-normalized AUC 0-24 was 1176 (HIV(-)), 791 (PI/r) and 473 (EFV) ng*hr/mL, and C24 was 32.7 (HIV(-)), 20.1 (PI/r), and 12.8 (EFV) ng/mL.","Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30788337/),[h·ng] / [ml],473,25167,DB01104,Sertraline
,30788337,C24,"Sertraline exposure was highest for HIV(-) and lowest for EFV cohorts; median dose-normalized AUC 0-24 was 1176 (HIV(-)), 791 (PI/r) and 473 (EFV) ng*hr/mL, and C24 was 32.7 (HIV(-)), 20.1 (PI/r), and 12.8 (EFV) ng/mL.","Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30788337/),[ng] / [ml],32.7,25168,DB01104,Sertraline
,30788337,C24,"Sertraline exposure was highest for HIV(-) and lowest for EFV cohorts; median dose-normalized AUC 0-24 was 1176 (HIV(-)), 791 (PI/r) and 473 (EFV) ng*hr/mL, and C24 was 32.7 (HIV(-)), 20.1 (PI/r), and 12.8 (EFV) ng/mL.","Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30788337/),[ng] / [ml],20.1,25169,DB01104,Sertraline
,30788337,C24,"Sertraline exposure was highest for HIV(-) and lowest for EFV cohorts; median dose-normalized AUC 0-24 was 1176 (HIV(-)), 791 (PI/r) and 473 (EFV) ng*hr/mL, and C24 was 32.7 (HIV(-)), 20.1 (PI/r), and 12.8 (EFV) ng/mL.","Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30788337/),[ng] / [ml],12.8,25170,DB01104,Sertraline
,14709940,elimination half-life,"Nefazodone was also the only antidepressant that caused a significant change in ALPZ disposition, decreasing its area under the concentration-versus-time curve (AUC; P < 0.01), and increasing its elimination half-life (16.4 vs. 12.3 hours; P < 0.05) compared with values at baseline.","Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14709940/),h,16.4,26950,DB01104,Sertraline
,14709940,elimination half-life,"Nefazodone was also the only antidepressant that caused a significant change in ALPZ disposition, decreasing its area under the concentration-versus-time curve (AUC; P < 0.01), and increasing its elimination half-life (16.4 vs. 12.3 hours; P < 0.05) compared with values at baseline.","Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14709940/),h,12.3,26951,DB01104,Sertraline
,16848750,S,The thermodynamic solubility of the hydrochloride salt (S = 4.24 +/- 0.02 mg/ml) and the free base form (S = 0.002 mg/ml) was measured by the saturation shake-flask method.,"Physico-chemical profiling of antidepressive sertraline: solubility, ionisation, lipophilicity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16848750/),[mg] / [ml],4.24,34354,DB01104,Sertraline
,16848750,S,The thermodynamic solubility of the hydrochloride salt (S = 4.24 +/- 0.02 mg/ml) and the free base form (S = 0.002 mg/ml) was measured by the saturation shake-flask method.,"Physico-chemical profiling of antidepressive sertraline: solubility, ionisation, lipophilicity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16848750/),[mg] / [ml],0.002,34355,DB01104,Sertraline
,16848750,dissociation constant (pKa,The co-solvent technique in methanol/water mixtures and the Yasuda-Shedlovsky extrapolation were applied for the determination of the dissociation constant (pKa = 9.16 +/- 0.02).,"Physico-chemical profiling of antidepressive sertraline: solubility, ionisation, lipophilicity. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16848750/),,9.16,34356,DB01104,Sertraline
,16848750,logPoct,The high lipophilicity value (logPoct = 4.30 +/- 0.01) of the nonionised form confirms the good absorption and distribution in the body.,"Physico-chemical profiling of antidepressive sertraline: solubility, ionisation, lipophilicity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16848750/),,4.30,34357,DB01104,Sertraline
,10190759,terminal elimination half-life,"administration, sertraline is slowly absorbed with peak plasma concentrations at 6 - 8 h, and has a terminal elimination half-life of approximately 26 h, indicating once-daily dosing is available.",Bioequivalence evaluation of two sertraline tablet formulations in healthy male volunteers after a single dose administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190759/),h,26,37541,DB01104,Sertraline
up to,10190759,plasma protein binding,"In addition, it also exhibits higher plasma protein binding up to 97% and extensive first-pass metabolism.",Bioequivalence evaluation of two sertraline tablet formulations in healthy male volunteers after a single dose administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190759/),,97,37542,DB01104,Sertraline
,11452243,area under the plasma concentration versus time curve (AUC(0-infinity)),Six poor metabolizers with m1 mutation had area under the plasma concentration versus time curve (AUC(0-infinity)) values (983.6 +/- 199.3 microg x h/L versus 697.6 +/- 133.0 microg x h/L; P <.05) and terminal elimination half-life values of sertraline (35.5 +/- 5.6 hours versus 23.5 +/- 4.4 hours; P <.01) that were significantly higher than the values in 6 extensive metabolizers who were either homozygous or heterozygous for CYP2C19*1.,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),[h·μg] / [l],983.6,39546,DB01104,Sertraline
,11452243,area under the plasma concentration versus time curve (AUC(0-infinity)),Six poor metabolizers with m1 mutation had area under the plasma concentration versus time curve (AUC(0-infinity)) values (983.6 +/- 199.3 microg x h/L versus 697.6 +/- 133.0 microg x h/L; P <.05) and terminal elimination half-life values of sertraline (35.5 +/- 5.6 hours versus 23.5 +/- 4.4 hours; P <.01) that were significantly higher than the values in 6 extensive metabolizers who were either homozygous or heterozygous for CYP2C19*1.,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),[h·μg] / [l],697.6,39547,DB01104,Sertraline
,11452243,terminal elimination half-life,Six poor metabolizers with m1 mutation had area under the plasma concentration versus time curve (AUC(0-infinity)) values (983.6 +/- 199.3 microg x h/L versus 697.6 +/- 133.0 microg x h/L; P <.05) and terminal elimination half-life values of sertraline (35.5 +/- 5.6 hours versus 23.5 +/- 4.4 hours; P <.01) that were significantly higher than the values in 6 extensive metabolizers who were either homozygous or heterozygous for CYP2C19*1.,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),h,35.5,39548,DB01104,Sertraline
,11452243,terminal elimination half-life,Six poor metabolizers with m1 mutation had area under the plasma concentration versus time curve (AUC(0-infinity)) values (983.6 +/- 199.3 microg x h/L versus 697.6 +/- 133.0 microg x h/L; P <.05) and terminal elimination half-life values of sertraline (35.5 +/- 5.6 hours versus 23.5 +/- 4.4 hours; P <.01) that were significantly higher than the values in 6 extensive metabolizers who were either homozygous or heterozygous for CYP2C19*1.,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),h,23.5,39549,DB01104,Sertraline
,11452243,oral clearance,The oral clearance of sertraline in poor metabolizers (105.3 +/- 19.4 L/h) was significantly lower than that of extensive metabolizers (148.4 +/- 28.6 L/h).,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),[l] / [h],105.3,39550,DB01104,Sertraline
,11452243,oral clearance,The oral clearance of sertraline in poor metabolizers (105.3 +/- 19.4 L/h) was significantly lower than that of extensive metabolizers (148.4 +/- 28.6 L/h).,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),[l] / [h],148.4,39551,DB01104,Sertraline
,11452243,area under the concentration-time curve from 0 to 144 hours,The area under the concentration-time curve from 0 to 144 hours and the maximum plasma concentration of desmethylsertraline in poor metabolizers were significantly lower than the values of extensive metabolizers (627.6 +/- 203.8 microg x h/L versus 972.1 +/- 270.3 microg x h/L; P <.05; and 23.6 +/- 6.5 nmol/L versus 32.4 +/- 8.2 nmol/L; P <.01; respectively).,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),[h·μg] / [l],627.6,39552,DB01104,Sertraline
,11452243,area under the concentration-time curve from 0 to 144 hours,The area under the concentration-time curve from 0 to 144 hours and the maximum plasma concentration of desmethylsertraline in poor metabolizers were significantly lower than the values of extensive metabolizers (627.6 +/- 203.8 microg x h/L versus 972.1 +/- 270.3 microg x h/L; P <.05; and 23.6 +/- 6.5 nmol/L versus 32.4 +/- 8.2 nmol/L; P <.01; respectively).,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),[h·μg] / [l],972.1,39553,DB01104,Sertraline
,11452243,maximum plasma concentration,The area under the concentration-time curve from 0 to 144 hours and the maximum plasma concentration of desmethylsertraline in poor metabolizers were significantly lower than the values of extensive metabolizers (627.6 +/- 203.8 microg x h/L versus 972.1 +/- 270.3 microg x h/L; P <.05; and 23.6 +/- 6.5 nmol/L versus 32.4 +/- 8.2 nmol/L; P <.01; respectively).,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),[nM] / [l],23.6,39554,DB01104,Sertraline
,11452243,maximum plasma concentration,The area under the concentration-time curve from 0 to 144 hours and the maximum plasma concentration of desmethylsertraline in poor metabolizers were significantly lower than the values of extensive metabolizers (627.6 +/- 203.8 microg x h/L versus 972.1 +/- 270.3 microg x h/L; P <.05; and 23.6 +/- 6.5 nmol/L versus 32.4 +/- 8.2 nmol/L; P <.01; respectively).,Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452243/),[nM] / [l],32.4,39555,DB01104,Sertraline
,8941024,total amount of,"The total amount of fluoxetine excreted in the urine during 8 days was almost three times higher in poor metabolizers than in extensive metabolizers (719 versus 225 micrograms; p < 0.05), whereas the total amount of norfluoxetine excreted in urine of poor metabolizers was about half of that of extensive metabolizers (524 versus 1047 micrograms; p < 0.05).",The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941024/),μg,524,39866,DB01104,Sertraline
,8941024,total amount of,"The total amount of fluoxetine excreted in the urine during 8 days was almost three times higher in poor metabolizers than in extensive metabolizers (719 versus 225 micrograms; p < 0.05), whereas the total amount of norfluoxetine excreted in urine of poor metabolizers was about half of that of extensive metabolizers (524 versus 1047 micrograms; p < 0.05).",The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941024/),μg,1047,39867,DB01104,Sertraline
,8941024,excreted,"The total amount of fluoxetine excreted in the urine during 8 days was almost three times higher in poor metabolizers than in extensive metabolizers (719 versus 225 micrograms; p < 0.05), whereas the total amount of norfluoxetine excreted in urine of poor metabolizers was about half of that of extensive metabolizers (524 versus 1047 micrograms; p < 0.05).",The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941024/),μg,524,39868,DB01104,Sertraline
,8941024,excreted,"The total amount of fluoxetine excreted in the urine during 8 days was almost three times higher in poor metabolizers than in extensive metabolizers (719 versus 225 micrograms; p < 0.05), whereas the total amount of norfluoxetine excreted in urine of poor metabolizers was about half of that of extensive metabolizers (524 versus 1047 micrograms; p < 0.05).",The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941024/),μg,1047,39869,DB01104,Sertraline
,8941024,partial metabolic clearance,"Norfluoxetine Cmax and AUCzero-->t were significantly smaller in poor metabolizers (decreases 55% and decreases 53%, respectively), and the partial metabolic clearance of fluoxetine into norfluoxetine was 10 times smaller in this group (4.3 +/- 1.9 versus 0.4 +/- 0.1 L/hr; p < 0.05).",The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941024/),[l] / [h],4.3,39870,DB01104,Sertraline
,8941024,partial metabolic clearance,"Norfluoxetine Cmax and AUCzero-->t were significantly smaller in poor metabolizers (decreases 55% and decreases 53%, respectively), and the partial metabolic clearance of fluoxetine into norfluoxetine was 10 times smaller in this group (4.3 +/- 1.9 versus 0.4 +/- 0.1 L/hr; p < 0.05).",The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941024/),[l] / [h],0.4,39871,DB01104,Sertraline
,21813341,Limits,"Limits of detection and quantification for both sertraline and desmethyl-sertraline were 0.30 and 1.00 μg/L, respectively.",Development and validation of an EI-GC/MS method for the determination of sertraline and its major metabolite desmethyl-sertraline in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21813341/),[μg] / [l],0.30,41679,DB01104,Sertraline
,21813341,Limits,"Limits of detection and quantification for both sertraline and desmethyl-sertraline were 0.30 and 1.00 μg/L, respectively.",Development and validation of an EI-GC/MS method for the determination of sertraline and its major metabolite desmethyl-sertraline in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21813341/),[μg] / [l],1.00,41680,DB01104,Sertraline
,21813341,Extraction efficiency,"Extraction efficiency ranged from 90.1(± 5.8)% to 95.4(± 3.0)% for sertraline, and from 84.9(± 8.2)% to 107.7(± 4.4)% for desmethyl-sertraline.",Development and validation of an EI-GC/MS method for the determination of sertraline and its major metabolite desmethyl-sertraline in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21813341/),%,90.1,41681,DB01104,Sertraline
,21813341,Extraction efficiency,"Extraction efficiency ranged from 90.1(± 5.8)% to 95.4(± 3.0)% for sertraline, and from 84.9(± 8.2)% to 107.7(± 4.4)% for desmethyl-sertraline.",Development and validation of an EI-GC/MS method for the determination of sertraline and its major metabolite desmethyl-sertraline in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21813341/),%,95.4,41682,DB01104,Sertraline
,21813341,Extraction efficiency,"Extraction efficiency ranged from 90.1(± 5.8)% to 95.4(± 3.0)% for sertraline, and from 84.9(± 8.2)% to 107.7(± 4.4)% for desmethyl-sertraline.",Development and validation of an EI-GC/MS method for the determination of sertraline and its major metabolite desmethyl-sertraline in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21813341/),%,84.9,41683,DB01104,Sertraline
,21813341,Extraction efficiency,"Extraction efficiency ranged from 90.1(± 5.8)% to 95.4(± 3.0)% for sertraline, and from 84.9(± 8.2)% to 107.7(± 4.4)% for desmethyl-sertraline.",Development and validation of an EI-GC/MS method for the determination of sertraline and its major metabolite desmethyl-sertraline in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21813341/),%,107.7,41684,DB01104,Sertraline
,16553533,maximum daily dose,Mean maximum daily dose at endpoint was 157 +/- 49 mg.,"Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16553533/),mg,157,43223,DB01104,Sertraline
,16553533,concentrations,"For female and male children, mean sertraline/N-desmethylsertraline concentrations normalized to a 200-mg dose were 85.0/160 ng/mL (n = 8) and 79.3/134 ng/mL (n = 8), respectively, and for female and male adolescents, 70.5/109 ng/mL (n = 16) and 76.3/120 ng/mL (n = 8).","Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16553533/),[ng] / [ml],85.0,43224,DB01104,Sertraline
,16553533,concentrations,"For female and male children, mean sertraline/N-desmethylsertraline concentrations normalized to a 200-mg dose were 85.0/160 ng/mL (n = 8) and 79.3/134 ng/mL (n = 8), respectively, and for female and male adolescents, 70.5/109 ng/mL (n = 16) and 76.3/120 ng/mL (n = 8).","Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16553533/),[ng] / [ml],160,43225,DB01104,Sertraline
,16553533,concentrations,"For female and male children, mean sertraline/N-desmethylsertraline concentrations normalized to a 200-mg dose were 85.0/160 ng/mL (n = 8) and 79.3/134 ng/mL (n = 8), respectively, and for female and male adolescents, 70.5/109 ng/mL (n = 16) and 76.3/120 ng/mL (n = 8).","Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16553533/),[ng] / [ml],79.3,43226,DB01104,Sertraline
,16553533,concentrations,"For female and male children, mean sertraline/N-desmethylsertraline concentrations normalized to a 200-mg dose were 85.0/160 ng/mL (n = 8) and 79.3/134 ng/mL (n = 8), respectively, and for female and male adolescents, 70.5/109 ng/mL (n = 16) and 76.3/120 ng/mL (n = 8).","Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16553533/),[ng] / [ml],134,43227,DB01104,Sertraline
,16553533,concentrations,"For female and male children, mean sertraline/N-desmethylsertraline concentrations normalized to a 200-mg dose were 85.0/160 ng/mL (n = 8) and 79.3/134 ng/mL (n = 8), respectively, and for female and male adolescents, 70.5/109 ng/mL (n = 16) and 76.3/120 ng/mL (n = 8).","Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16553533/),[ng] / [ml],70.5,43228,DB01104,Sertraline
,16553533,concentrations,"For female and male children, mean sertraline/N-desmethylsertraline concentrations normalized to a 200-mg dose were 85.0/160 ng/mL (n = 8) and 79.3/134 ng/mL (n = 8), respectively, and for female and male adolescents, 70.5/109 ng/mL (n = 16) and 76.3/120 ng/mL (n = 8).","Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16553533/),[ng] / [ml],76.3,43229,DB01104,Sertraline
,7992822,elimination half-lives,"The selective serotonin reuptake inhibitors (SSRIs)--paroxetine, sertraline, and fluvoxamine--have elimination half-lives of 15-26 hours.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),h,15-26,43464,DB01104,Sertraline
,7992822,half-life,"The extended half-life of fluoxetine (4-6 days) and its active metabolite, norfluoxetine (4-16 days), results in an extended time to steady-state and a prolonged washout period when dosing is discontinued.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),d,4-6,43465,DB01104,Sertraline
,7992822,half-life,"The extended half-life of fluoxetine (4-6 days) and its active metabolite, norfluoxetine (4-16 days), results in an extended time to steady-state and a prolonged washout period when dosing is discontinued.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),d,4-16,43466,DB01104,Sertraline
,7992822,half-lives,"Venlafaxine and nefazodone have short half-lives, 2-5 hours, and are dosed > or = 2 times daily.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),h,2-5,43467,DB01104,Sertraline
,27060853,Half-life,Half-life and sex effect on sertraline apparent clearance (males averaging 50% higher (p < 0.005); 96.6 l/h vs 64.8 in female subjects) were similar to previous reports.,"SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27060853/),[l] / [h],96.6,54033,DB01104,Sertraline
,27060853,apparent clearance,Half-life and sex effect on sertraline apparent clearance (males averaging 50% higher (p < 0.005); 96.6 l/h vs 64.8 in female subjects) were similar to previous reports.,"SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27060853/),[l] / [h],96.6,54034,DB01104,Sertraline
,27060853,apparent clearance,Half-life and sex effect on sertraline apparent clearance (males averaging 50% higher (p < 0.005); 96.6 l/h vs 64.8 in female subjects) were similar to previous reports.,"SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27060853/),,64.8,54035,DB01104,Sertraline
less,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,24,56611,DB01104,Sertraline
,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),d,2,56612,DB01104,Sertraline
,7834966,tmax,"All 3 of the structurally unique newer antidepressants [amfebutamone (bupropion), viloxazine venlafaxine] have relatively short tmax values (1 to 2 hours), which may relate to the early onset of adverse effects.",Pharmacokinetic optimisation of therapy with newer antidepressants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,1 to 2,56613,DB01104,Sertraline
,11996499,detection limit,"The detection limit for the SIM of sertraline as an N-HFB derivative was 0.1 ng/ml, and its recovery was 80-85%.",Rapid and sensitive determination of sertraline in human plasma using gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996499/),[ng] / [ml],0.1,62548,DB01104,Sertraline
,11996499,recovery,"The detection limit for the SIM of sertraline as an N-HFB derivative was 0.1 ng/ml, and its recovery was 80-85%.",Rapid and sensitive determination of sertraline in human plasma using gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996499/),%,80-85,62549,DB01104,Sertraline
,11996499,Cmax,"After pharmacokinetics was performed with this assay method following oral administration of sertraline hydrochloride in man, moment analysis revealed that pharmacokinetic parameters for sertraline (Cmax, 10.3 ng/ml; Tmax, 8.0 h; T(1/2) 28.6 h) were similar to previously reported results.",Rapid and sensitive determination of sertraline in human plasma using gas chromatography-mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996499/),[ng] / [ml],10.3,62550,DB01104,Sertraline
,11996499,Tmax,"After pharmacokinetics was performed with this assay method following oral administration of sertraline hydrochloride in man, moment analysis revealed that pharmacokinetic parameters for sertraline (Cmax, 10.3 ng/ml; Tmax, 8.0 h; T(1/2) 28.6 h) were similar to previously reported results.",Rapid and sensitive determination of sertraline in human plasma using gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996499/),h,8.0,62551,DB01104,Sertraline
,11996499,T(1/2),"After pharmacokinetics was performed with this assay method following oral administration of sertraline hydrochloride in man, moment analysis revealed that pharmacokinetic parameters for sertraline (Cmax, 10.3 ng/ml; Tmax, 8.0 h; T(1/2) 28.6 h) were similar to previously reported results.",Rapid and sensitive determination of sertraline in human plasma using gas chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996499/),h,28.6,62552,DB01104,Sertraline
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),d,1 and 4,62758,DB01104,Sertraline
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),d,7 and 15,62759,DB01104,Sertraline
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),h,21,62760,DB01104,Sertraline
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),h,36,62761,DB01104,Sertraline
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,11,63198,DB01104,Sertraline
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,83,63199,DB01104,Sertraline
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,24,63200,DB01104,Sertraline
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,20,63201,DB01104,Sertraline
,7946933,liver:water partition ratios,"4. The in vitro data predict 29% inhibition of ALP clearance at mean FLU and NOR plasma concentrations of 77 ng ml-1 and 72 ng ml-1, respectively, after correction for liver:water partition ratios in the range of 12-14.","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),,12-14,63202,DB01104,Sertraline
,7946933,Ki,"5. Ketoconazole was a potent inhibitor of ALP metabolism in vitro (Ki = 0.046 microM), suggesting that ALP hydroxylation is mediated by the cytochrome P450-3A sub-family.","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,0.046,63203,DB01104,Sertraline
,7946933,Ki,Quinidine was a weak inhibitor (Ki = 626 microM).,"Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,626,63204,DB01104,Sertraline
,2573498,volume of distribution,"The whole brain concentration of sertraline in the rat is more than 40-fold higher than that in plasma, and the volume of distribution is about 25 liters/kg in the rat and dog.",Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573498/),[l] / [kg],25,72857,DB01104,Sertraline
greater,2573498,metabolic clearance,"The metabolic clearance of sertraline is greater than 35 ml of blood/min/kg in each species, and first-pass metabolism occurs with oral administration.",Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573498/),[blood·ml] / [kg·min],35,72858,DB01104,Sertraline
,19912165,half-life,The in vivo half-life predicted for timolol was 3.7 hr.,Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),h,3.7,82486,DB01104,Sertraline
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,1.4,82487,DB01104,Sertraline
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,2.0,82488,DB01104,Sertraline
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,3.5,82489,DB01104,Sertraline
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,21,82490,DB01104,Sertraline
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,20,82491,DB01104,Sertraline
,19912165,IC(50),"In human cryo-preserved hepatocytes, the IC(50) values for fluoxetine, paroxetine and fluvoxamine were 0.7, 0.5 and 5.9 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,0.7,82492,DB01104,Sertraline
,19912165,IC(50),"In human cryo-preserved hepatocytes, the IC(50) values for fluoxetine, paroxetine and fluvoxamine were 0.7, 0.5 and 5.9 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,0.5,82493,DB01104,Sertraline
,19912165,IC(50),"In human cryo-preserved hepatocytes, the IC(50) values for fluoxetine, paroxetine and fluvoxamine were 0.7, 0.5 and 5.9 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,5.9,82494,DB01104,Sertraline
,30919786,bioavailability,Poor bioavailability (around 44%) of hydrochloride salt is considered to be conversion of salts to free base in the gastrointestinal tract which retard it's absorption.,Systematic Development of Sertraline Loaded Solid Lipid Nanoparticle (SLN) by Emulsification-Ultrasonication Method and Pharmacokinetic Study in Sprague-Dawley Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919786/),%,44,97187,DB01104,Sertraline
,30919786,sonication time (ST),"SLN with <110 nm size, <0.2 PDI, >36 mV ZP, >72% EE, and nearly 0.7% L can be formed at appropriate formulation process conditions; homogenization time (HT) and sonication time (ST) at 5 min and 10 min, respectively.",Systematic Development of Sertraline Loaded Solid Lipid Nanoparticle (SLN) by Emulsification-Ultrasonication Method and Pharmacokinetic Study in Sprague-Dawley Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919786/),,10,97188,DB01104,Sertraline
,30919786,zeta potential,The optimized SLN formulation have shown the highest value of zeta potential (-36.5 mV) confers stability of nanodispersion.,Systematic Development of Sertraline Loaded Solid Lipid Nanoparticle (SLN) by Emulsification-Ultrasonication Method and Pharmacokinetic Study in Sprague-Dawley Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919786/),mv,-,97189,DB01104,Sertraline
,30919786,zeta potential,The optimized SLN formulation have shown the highest value of zeta potential (-36.5 mV) confers stability of nanodispersion.,Systematic Development of Sertraline Loaded Solid Lipid Nanoparticle (SLN) by Emulsification-Ultrasonication Method and Pharmacokinetic Study in Sprague-Dawley Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919786/),mv,36.5,97190,DB01104,Sertraline
,9068933,terminal elimination half-life,"The terminal elimination rate constant was also significantly reduced, corresponding to the increase in the terminal elimination half-life (from 6.9 to 8.6 hours).",A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068933/),h,6.9,97926,DB01104,Sertraline
,9068933,terminal elimination half-life,"The terminal elimination rate constant was also significantly reduced, corresponding to the increase in the terminal elimination half-life (from 6.9 to 8.6 hours).",A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068933/),h,8.6,97927,DB01104,Sertraline
,21256091,AUC(0-10.5),"The mean AUC(0-10.5) was significantly smaller for the postbariatric surgery group (124.4 ± 55.5 ng-hr/mL, range 62.0-198.1; P = .043) compared with the nonsurgical control group (314.8 ± 129.6 ng-hr/mL, range 194.8-508.7).",Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256091/),[ng-hr] / [ml],124.4,104381,DB01104,Sertraline
,21256091,AUC(0-10.5),"The mean AUC(0-10.5) was significantly smaller for the postbariatric surgery group (124.4 ± 55.5 ng-hr/mL, range 62.0-198.1; P = .043) compared with the nonsurgical control group (314.8 ± 129.6 ng-hr/mL, range 194.8-508.7).",Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256091/),[ng-hr] / [ml],314.8,104382,DB01104,Sertraline
,12590627,milk/plasma ratio,"The milk/plasma ratio was highly variable (range, 0.42-4.81).",The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12590627/),,0.42-4.81,105953,DB01104,Sertraline
,1806626,elimination half-life,The elimination half-life is about 32 h; metabolism is by demethylation to an inactive metabolite.,Clinical implications of the pharmacology of sertraline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1806626/),h,32,117841,DB01104,Sertraline
,23109441,t(1/2),"This analytical method was successfully applied to characterize sertraline pharmacokinetics in rats following intravenous (t(1/2) = 213 ± 48 min, Cl = 43.1 ± 8.7 mL/min, V(d) = 11560 ± 1861 mL) and oral (C(max) = 156 ± 76 ng/mL, t(max) = 63.8 ± 16.3 min) administration of 2 and 5 mg, respectively.",Determination of sertraline in rat plasma by HPLC and fluorescence detection and its application to in vivo pharmacokinetic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109441/),min,213,118468,DB01104,Sertraline
,23109441,Cl,"This analytical method was successfully applied to characterize sertraline pharmacokinetics in rats following intravenous (t(1/2) = 213 ± 48 min, Cl = 43.1 ± 8.7 mL/min, V(d) = 11560 ± 1861 mL) and oral (C(max) = 156 ± 76 ng/mL, t(max) = 63.8 ± 16.3 min) administration of 2 and 5 mg, respectively.",Determination of sertraline in rat plasma by HPLC and fluorescence detection and its application to in vivo pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109441/),[ml] / [min],43.1,118469,DB01104,Sertraline
,23109441,V(d),"This analytical method was successfully applied to characterize sertraline pharmacokinetics in rats following intravenous (t(1/2) = 213 ± 48 min, Cl = 43.1 ± 8.7 mL/min, V(d) = 11560 ± 1861 mL) and oral (C(max) = 156 ± 76 ng/mL, t(max) = 63.8 ± 16.3 min) administration of 2 and 5 mg, respectively.",Determination of sertraline in rat plasma by HPLC and fluorescence detection and its application to in vivo pharmacokinetic studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109441/),ml,11560,118470,DB01104,Sertraline
,23109441,C(max),"This analytical method was successfully applied to characterize sertraline pharmacokinetics in rats following intravenous (t(1/2) = 213 ± 48 min, Cl = 43.1 ± 8.7 mL/min, V(d) = 11560 ± 1861 mL) and oral (C(max) = 156 ± 76 ng/mL, t(max) = 63.8 ± 16.3 min) administration of 2 and 5 mg, respectively.",Determination of sertraline in rat plasma by HPLC and fluorescence detection and its application to in vivo pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109441/),[ng] / [ml],156,118471,DB01104,Sertraline
,23109441,t(max),"This analytical method was successfully applied to characterize sertraline pharmacokinetics in rats following intravenous (t(1/2) = 213 ± 48 min, Cl = 43.1 ± 8.7 mL/min, V(d) = 11560 ± 1861 mL) and oral (C(max) = 156 ± 76 ng/mL, t(max) = 63.8 ± 16.3 min) administration of 2 and 5 mg, respectively.",Determination of sertraline in rat plasma by HPLC and fluorescence detection and its application to in vivo pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109441/),min,63.8,118472,DB01104,Sertraline
,22426846,dose corrected concentration,"The dose corrected concentration of lamotrigine in patients receiving lamotrigine in combination with sertraline was 60.4 μmol/L × 1,000/mg/day (SD: 31.1) (N = 7) compared to 51.1 μmol/L × 1 000/mg/day (SD: 27.6) (N = 44) in patients using lamotrigine without sertraline (p = 0.42).",Lack of interaction between sertraline and lamotrigine in psychiatric patients: a retrospective study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22426846/),"[μM] / [1,000·d·l·mg]",60.4,120941,DB01104,Sertraline
,22426846,dose corrected concentration,"The dose corrected concentration of lamotrigine in patients receiving lamotrigine in combination with sertraline was 60.4 μmol/L × 1,000/mg/day (SD: 31.1) (N = 7) compared to 51.1 μmol/L × 1 000/mg/day (SD: 27.6) (N = 44) in patients using lamotrigine without sertraline (p = 0.42).",Lack of interaction between sertraline and lamotrigine in psychiatric patients: a retrospective study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22426846/),[μM] / [000·1·d·l·mg],51.1,120942,DB01104,Sertraline
,26324195,flow rate,Chromatographic separation was carried out on an Acquity UPLC BEH C18 column using a gradient mobile phase system composed of acetonitrile and 1% formic acid in water at a flow rate of 0.40 mL/min.,Determination of Sertraline in Human Plasma by UPLC-MS/MS and its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26324195/),[ml] / [min],0.40,121065,DB01104,Sertraline
,9068931,half-life (t1/2),Most SSRIs have a half-life (t1/2) of approximately 1 day.,Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068931/),d,1,129521,DB01104,Sertraline
,9068931,t1/2,"Fluoxetine, however, has a longer t1/2 of 2 to 4 days, and its active metabolite, norfluoxetine, has an extended t1/2 of 7 to 15 days.",Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068931/),d,2 to 4,129522,DB01104,Sertraline
,9068931,t1/2,"Fluoxetine, however, has a longer t1/2 of 2 to 4 days, and its active metabolite, norfluoxetine, has an extended t1/2 of 7 to 15 days.",Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068931/),d,7 to 15,129523,DB01104,Sertraline
,9679303,Recoveries,"Recoveries measured at three concentrations range from 81 to 118% for the tertiary amines (citalopram and the internal standard methylmaprotiline), 73 to 95% for the secondary amines (desmethylcitalopram, paroxetine and sertraline), and 39 to 66% for the primary amines (didesmethylcitalopram and desmethylsertraline).","Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9679303/),%,81 to 118,129741,DB01104,Sertraline
,9679303,Recoveries,"Recoveries measured at three concentrations range from 81 to 118% for the tertiary amines (citalopram and the internal standard methylmaprotiline), 73 to 95% for the secondary amines (desmethylcitalopram, paroxetine and sertraline), and 39 to 66% for the primary amines (didesmethylcitalopram and desmethylsertraline).","Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9679303/),%,73 to 95,129742,DB01104,Sertraline
,9679303,Recoveries,"Recoveries measured at three concentrations range from 81 to 118% for the tertiary amines (citalopram and the internal standard methylmaprotiline), 73 to 95% for the secondary amines (desmethylcitalopram, paroxetine and sertraline), and 39 to 66% for the primary amines (didesmethylcitalopram and desmethylsertraline).","Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9679303/),%,39 to 66,129743,DB01104,Sertraline
,1531816,elimination half-life,"With the exception of fluoxetine, which has an elimination half-life of 2 to 3 days, the other drugs have half-lives of about 1 day.",Pharmacokinetics of the selective serotonin reuptake inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531816/),d,2 to 3,152373,DB01104,Sertraline
,1531816,half-lives,"With the exception of fluoxetine, which has an elimination half-life of 2 to 3 days, the other drugs have half-lives of about 1 day.",Pharmacokinetics of the selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531816/),d,1,152374,DB01104,Sertraline
,17099560,bioavailability,Its mean bioavailability is around 75%.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),%,75,153478,DB01104,Sertraline
,17099560,volume of distribution,Its volume of distribution is of around 4 L/kg.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),[l] / [kg],4,153479,DB01104,Sertraline
,17099560,half-life elimination,The value of half-life elimination is of around 22 hours.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),h,22,153480,DB01104,Sertraline
,17099560,bioavibility,"Thus, bioavibility ranges from 36 to 100%.",[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),%,36 to 100,153481,DB01104,Sertraline
,17099560,plasmatic target,The methadone plasmatic target value of 400 microg/ml can be recommended for therapeutic drug monitoring.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),[μg] / [ml],400,153482,DB01104,Sertraline
,9643617,milk production,Mean milk production was 321 ml day(-1) (range 34-974 ml).,Distribution and excretion of sertraline and N-desmethylsertraline in human milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643617/),[ml] / [day],321,154446,DB01104,Sertraline
,9643617,M/P,Mean M/P values of 1.93 and 1.64 were calculated for sertraline and N-desmethylsertraline respectively.,Distribution and excretion of sertraline and N-desmethylsertraline in human milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643617/),,1.93,154447,DB01104,Sertraline
,9643617,M/P,Mean M/P values of 1.93 and 1.64 were calculated for sertraline and N-desmethylsertraline respectively.,Distribution and excretion of sertraline and N-desmethylsertraline in human milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643617/),,1.64,154448,DB01104,Sertraline
,32957789,flow rate,"The analytes of interest and internal standard (duloxetine (DUL)) were extracted from 100 μL of plasma with solid-phase extraction on an Oasis HLB cartridge followed by the separation with gradient elution with water containing 0.1% formic acid and acetonitrile on an Agilent Eclipse Plus ODS (4.6 × 100 mm, 3.5 μm) column at flow rate 0.2 mL min-1.","Toxicity Profile, Pharmacokinetic, and Drug-Drug Interaction Study of Citalopram and Sertraline Following Oral Delivery in Rat: An LC-MS/MS Method for the Simultaneous Determination in Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32957789/),[ml] / [min],0.2,168143,DB01104,Sertraline
,11936581,terminal half-life,"Blood aldicarb level was 3.11 microg/mL at T0 and peaked at T0+3.5 h (3.22 microg/mL), then followed a two-slope decay with a terminal half-life of ca. 20 h.",Repeated measurements of aldicarb in blood and urine in a case of nonfatal poisoning. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936581/),h,20,169378,DB01104,Sertraline
,11936581,peak level,Aldicarb was detected in all urine samples (peak level: 6.95 microg/mL at T0+31.5 h) and was still present at the time of discharge.,Repeated measurements of aldicarb in blood and urine in a case of nonfatal poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936581/),[μg] / [ml],6.95,169379,DB01104,Sertraline
,16213473,K(D),Occupation of 5-HTT sites saturates at low plasma sertraline levels (K(D) = 1.9 ng/ml) with maximal occupancies of 106.8 +/- 8.3% across all brain regions.,Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16213473/),[ng] / [ml],1.9,188042,DB01104,Sertraline
,16213473,maximal occupancies,Occupation of 5-HTT sites saturates at low plasma sertraline levels (K(D) = 1.9 ng/ml) with maximal occupancies of 106.8 +/- 8.3% across all brain regions.,Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16213473/),%,106.8,188043,DB01104,Sertraline
,15547048,overall K(m),"In human liver microsomes, sertraline was N-demethylated and deaminated by cytochrome P450 (P450) enzymes with overall K(m) values of 98 and 114 microM, respectively, but the intrinsic clearance for N-demethylation was approximately 20-fold greater than for deamination.","Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15547048/),μM,98,189931,DB01104,Sertraline
,15547048,overall K(m),"In human liver microsomes, sertraline was N-demethylated and deaminated by cytochrome P450 (P450) enzymes with overall K(m) values of 98 and 114 microM, respectively, but the intrinsic clearance for N-demethylation was approximately 20-fold greater than for deamination.","Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15547048/),μM,114,189932,DB01104,Sertraline
,15547048,K(m),Purified human monoamine oxidases A and B also catalyzed sertraline deamination with comparable K(m) values (230-270 microM).,"Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15547048/),μM,230-270,189933,DB01104,Sertraline
,15547048,K(m),Sertraline N-carbamoyl glucuronidation was measured in human liver microsomes in bicarbonate buffer and under a CO2 atmosphere (K(m) = 50 microM) and was catalyzed at the fastest rate by recombinant human UGT2B7.,"Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15547048/),μM,50,189934,DB01104,Sertraline
,9241008,maximum concentration in plasma (Cmax),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[ng] / [ml],37.8 to 173,192832,DB01104,Sertraline
,9241008,maximum concentration in plasma (Cmax),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[ng] / [ml],36.1 to 51.9,192833,DB01104,Sertraline
,9241008,area under the concentration-time curve (AUC[24]),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[h·ng] / [ml],"634 to 3,305",192834,DB01104,Sertraline
,9241008,area under the concentration-time curve (AUC[24]),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[h·ng] / [ml],611 to 838,192835,DB01104,Sertraline
,9241008,trough value (C0),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[ng] / [ml],18.5 to 113,192836,DB01104,Sertraline
,9241008,trough value (C0),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[ng] / [ml],18.3 to 21.8,192837,DB01104,Sertraline
,22011692,tmax,"After the administration of sertraline at 5 mg, 25 mg and 50 mg, the median tmax were 6.0, 6.0 and 4.0 h and the mean (SD) elimination half-lives were 31.9 (6.5), 27.2 (6.7) and 28.0 (6.6) h, respectively.","Open label, three period, single sequence, study of 5, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011692/),h,6.0,196608,DB01104,Sertraline
,22011692,tmax,"After the administration of sertraline at 5 mg, 25 mg and 50 mg, the median tmax were 6.0, 6.0 and 4.0 h and the mean (SD) elimination half-lives were 31.9 (6.5), 27.2 (6.7) and 28.0 (6.6) h, respectively.","Open label, three period, single sequence, study of 5, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011692/),h,4.0,196609,DB01104,Sertraline
,22011692,elimination half-lives,"After the administration of sertraline at 5 mg, 25 mg and 50 mg, the median tmax were 6.0, 6.0 and 4.0 h and the mean (SD) elimination half-lives were 31.9 (6.5), 27.2 (6.7) and 28.0 (6.6) h, respectively.","Open label, three period, single sequence, study of 5, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011692/),h,31.9,196610,DB01104,Sertraline
,22011692,elimination half-lives,"After the administration of sertraline at 5 mg, 25 mg and 50 mg, the median tmax were 6.0, 6.0 and 4.0 h and the mean (SD) elimination half-lives were 31.9 (6.5), 27.2 (6.7) and 28.0 (6.6) h, respectively.","Open label, three period, single sequence, study of 5, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011692/),h,27.2,196611,DB01104,Sertraline
,22011692,elimination half-lives,"After the administration of sertraline at 5 mg, 25 mg and 50 mg, the median tmax were 6.0, 6.0 and 4.0 h and the mean (SD) elimination half-lives were 31.9 (6.5), 27.2 (6.7) and 28.0 (6.6) h, respectively.","Open label, three period, single sequence, study of 5, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011692/),h,28.0,196612,DB01104,Sertraline
,22011692,AUC,"The dose-normalized mean (SD) AUC and Cmax were different in each dosing group (p < 0.01) with 2.0 (0.8), 5.3 (1.2) and 6.0 (1.9) mg × hr/l/mg in the 5 mg, 25 mg and 50 mg groups for dose-normalized AUC, and 0.07 (0.01), 0.18 (0.05) and 0.21 (0.08) mg/l/mg in the 5 mg, 25 mg and 50 mg groups for dose-normalized Cmax, respectively, which indicates a lack of dose proportionality.","Open label, three period, single sequence, study of 5, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011692/),[h·mg] / [l·mg],2.0,196613,DB01104,Sertraline
,22011692,AUC,"The dose-normalized mean (SD) AUC and Cmax were different in each dosing group (p < 0.01) with 2.0 (0.8), 5.3 (1.2) and 6.0 (1.9) mg × hr/l/mg in the 5 mg, 25 mg and 50 mg groups for dose-normalized AUC, and 0.07 (0.01), 0.18 (0.05) and 0.21 (0.08) mg/l/mg in the 5 mg, 25 mg and 50 mg groups for dose-normalized Cmax, respectively, which indicates a lack of dose proportionality.","Open label, three period, single sequence, study of 5, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011692/),[h·mg] / [l·mg],5.3,196614,DB01104,Sertraline
,22011692,Cmax,"The dose-normalized mean (SD) AUC and Cmax were different in each dosing group (p < 0.01) with 2.0 (0.8), 5.3 (1.2) and 6.0 (1.9) mg × hr/l/mg in the 5 mg, 25 mg and 50 mg groups for dose-normalized AUC, and 0.07 (0.01), 0.18 (0.05) and 0.21 (0.08) mg/l/mg in the 5 mg, 25 mg and 50 mg groups for dose-normalized Cmax, respectively, which indicates a lack of dose proportionality.","Open label, three period, single sequence, study of 5, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011692/),[h·mg] / [l·mg],5.3,196615,DB01104,Sertraline
,22011692,Cmax,"The dose-normalized mean (SD) AUC and Cmax were different in each dosing group (p < 0.01) with 2.0 (0.8), 5.3 (1.2) and 6.0 (1.9) mg × hr/l/mg in the 5 mg, 25 mg and 50 mg groups for dose-normalized AUC, and 0.07 (0.01), 0.18 (0.05) and 0.21 (0.08) mg/l/mg in the 5 mg, 25 mg and 50 mg groups for dose-normalized Cmax, respectively, which indicates a lack of dose proportionality.","Open label, three period, single sequence, study of 5, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011692/),[h·mg] / [l·mg],6.0,196616,DB01104,Sertraline
,22011692,AUC,"The dose-normalized mean (SD) AUC and Cmax were different in each dosing group (p < 0.01) with 2.0 (0.8), 5.3 (1.2) and 6.0 (1.9) mg × hr/l/mg in the 5 mg, 25 mg and 50 mg groups for dose-normalized AUC, and 0.07 (0.01), 0.18 (0.05) and 0.21 (0.08) mg/l/mg in the 5 mg, 25 mg and 50 mg groups for dose-normalized Cmax, respectively, which indicates a lack of dose proportionality.","Open label, three period, single sequence, study of 5, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011692/),[mg] / [l·mg],0.18,196617,DB01104,Sertraline
,22011692,AUC,"The dose-normalized mean (SD) AUC and Cmax were different in each dosing group (p < 0.01) with 2.0 (0.8), 5.3 (1.2) and 6.0 (1.9) mg × hr/l/mg in the 5 mg, 25 mg and 50 mg groups for dose-normalized AUC, and 0.07 (0.01), 0.18 (0.05) and 0.21 (0.08) mg/l/mg in the 5 mg, 25 mg and 50 mg groups for dose-normalized Cmax, respectively, which indicates a lack of dose proportionality.","Open label, three period, single sequence, study of 5, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011692/),[mg] / [l·mg],0.21,196618,DB01104,Sertraline
,22011692,Cmax,"The dose-normalized mean (SD) AUC and Cmax were different in each dosing group (p < 0.01) with 2.0 (0.8), 5.3 (1.2) and 6.0 (1.9) mg × hr/l/mg in the 5 mg, 25 mg and 50 mg groups for dose-normalized AUC, and 0.07 (0.01), 0.18 (0.05) and 0.21 (0.08) mg/l/mg in the 5 mg, 25 mg and 50 mg groups for dose-normalized Cmax, respectively, which indicates a lack of dose proportionality.","Open label, three period, single sequence, study of 5, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011692/),[mg] / [l·mg],0.07,196619,DB01104,Sertraline
,22011692,Cmax,"The dose-normalized mean (SD) AUC and Cmax were different in each dosing group (p < 0.01) with 2.0 (0.8), 5.3 (1.2) and 6.0 (1.9) mg × hr/l/mg in the 5 mg, 25 mg and 50 mg groups for dose-normalized AUC, and 0.07 (0.01), 0.18 (0.05) and 0.21 (0.08) mg/l/mg in the 5 mg, 25 mg and 50 mg groups for dose-normalized Cmax, respectively, which indicates a lack of dose proportionality.","Open label, three period, single sequence, study of 5, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011692/),[mg] / [l·mg],0.18,196620,DB01104,Sertraline
,22011692,Cmax,"The dose-normalized mean (SD) AUC and Cmax were different in each dosing group (p < 0.01) with 2.0 (0.8), 5.3 (1.2) and 6.0 (1.9) mg × hr/l/mg in the 5 mg, 25 mg and 50 mg groups for dose-normalized AUC, and 0.07 (0.01), 0.18 (0.05) and 0.21 (0.08) mg/l/mg in the 5 mg, 25 mg and 50 mg groups for dose-normalized Cmax, respectively, which indicates a lack of dose proportionality.","Open label, three period, single sequence, study of 5, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011692/),[mg] / [l·mg],0.21,196621,DB01104,Sertraline
,10445388,Ki,"In vitro studies with control liver microsomes, as well as with microsomes of rats treated chronically with fluoxetine show that the changes in the thioridazine pharmacokinetics may be attributed to the competitive (N-demethylation, Ki = 23 microM) and mixed inhibition (2- and 5-sulfoxidation, Ki = 60 microM and 34 microM, respectively) of thioridazine metabolism by fluoxetine, and to the adaptive changes produced by chronic administration of fluoxetine, as reflected by inhibition of N-demethylation and formation of sulforidazine.",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,23,199315,DB01104,Sertraline
,10445388,Ki,"In vitro studies with control liver microsomes, as well as with microsomes of rats treated chronically with fluoxetine show that the changes in the thioridazine pharmacokinetics may be attributed to the competitive (N-demethylation, Ki = 23 microM) and mixed inhibition (2- and 5-sulfoxidation, Ki = 60 microM and 34 microM, respectively) of thioridazine metabolism by fluoxetine, and to the adaptive changes produced by chronic administration of fluoxetine, as reflected by inhibition of N-demethylation and formation of sulforidazine.",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,60,199316,DB01104,Sertraline
,10445388,Ki,"In vitro studies with control liver microsomes, as well as with microsomes of rats treated chronically with fluoxetine show that the changes in the thioridazine pharmacokinetics may be attributed to the competitive (N-demethylation, Ki = 23 microM) and mixed inhibition (2- and 5-sulfoxidation, Ki = 60 microM and 34 microM, respectively) of thioridazine metabolism by fluoxetine, and to the adaptive changes produced by chronic administration of fluoxetine, as reflected by inhibition of N-demethylation and formation of sulforidazine.",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,34,199317,DB01104,Sertraline
,10445388,Ki,"Sertraline seemed to have a tendency to decrease thioridazine concentration in vivo, though in vitro studies showed that - like fluoxetine - it competitively or via mixed mechanism inhibited the three metabolic pathways of thioridazine (Ki = 41 microM, 64 microM and 47 microM, respectively).",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,41,199318,DB01104,Sertraline
,10445388,Ki,"Sertraline seemed to have a tendency to decrease thioridazine concentration in vivo, though in vitro studies showed that - like fluoxetine - it competitively or via mixed mechanism inhibited the three metabolic pathways of thioridazine (Ki = 41 microM, 64 microM and 47 microM, respectively).",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,64,199319,DB01104,Sertraline
,10445388,Ki,"Sertraline seemed to have a tendency to decrease thioridazine concentration in vivo, though in vitro studies showed that - like fluoxetine - it competitively or via mixed mechanism inhibited the three metabolic pathways of thioridazine (Ki = 41 microM, 64 microM and 47 microM, respectively).",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,47,199320,DB01104,Sertraline
,10445388,Ki,"In the case of fluvoxamine, a tendency to increase the thioridazine level was observed, which may be connected with the competitive or mixed inhibition of thioridazine N-demethylation and 2-sulfoxidation by the antidepressant (Ki = 17 microM and 167 microM, respectively).",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,17,199321,DB01104,Sertraline
,10445388,Ki,"In the case of fluvoxamine, a tendency to increase the thioridazine level was observed, which may be connected with the competitive or mixed inhibition of thioridazine N-demethylation and 2-sulfoxidation by the antidepressant (Ki = 17 microM and 167 microM, respectively).",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,167,199322,DB01104,Sertraline
,8384945,Absolute bioavailability,"Absolute bioavailability of citalopram is almost 100%, whereas it is likely that the other compounds undergo (substantial) first-pass metabolism.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,100,201450,DB01104,Sertraline
,8384945,Apparent oral clearance,"Apparent oral clearance values after single doses range from 26 L/h (citalopram) to 167 L/h (paroxetine), while after multiple doses oral clearance is markedly reduced, particularly for fluoxetine and paroxetine.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),[l] / [h],26,201451,DB01104,Sertraline
,8384945,Apparent oral clearance,"Apparent oral clearance values after single doses range from 26 L/h (citalopram) to 167 L/h (paroxetine), while after multiple doses oral clearance is markedly reduced, particularly for fluoxetine and paroxetine.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),[l] / [h],167,201452,DB01104,Sertraline
> or =,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,95,201453,DB01104,Sertraline
,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,77,201454,DB01104,Sertraline
,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,50,201455,DB01104,Sertraline
,8384945,half-lives,"The half-lives of fluvoxamine, paroxetine, sertraline and citalopram are approximately 1 day.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,1,201456,DB01104,Sertraline
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,2,201457,DB01104,Sertraline
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,6,201458,DB01104,Sertraline
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,7 to 15,201459,DB01104,Sertraline
,12218424,steady-state half-life,"The mean steady-state half-life of 50 mg was significantly shorter (15.3 +/- 3.5 hours) than the single-dose half-life (26.7 +/- 5.2 hours; t = 6.4, p < .001) and the steady-state half-life at 100 to 150 mg/day (20.4 +/- 3.4 hours; t = 2.9, p = .01).",Sertraline pharmacokinetics and dynamics in adolescents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12218424/),h,15.3,207900,DB01104,Sertraline
,12218424,half-life,"The mean steady-state half-life of 50 mg was significantly shorter (15.3 +/- 3.5 hours) than the single-dose half-life (26.7 +/- 5.2 hours; t = 6.4, p < .001) and the steady-state half-life at 100 to 150 mg/day (20.4 +/- 3.4 hours; t = 2.9, p = .01).",Sertraline pharmacokinetics and dynamics in adolescents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12218424/),h,26.7,207901,DB01104,Sertraline
,12218424,steady-state half-life,"The mean steady-state half-life of 50 mg was significantly shorter (15.3 +/- 3.5 hours) than the single-dose half-life (26.7 +/- 5.2 hours; t = 6.4, p < .001) and the steady-state half-life at 100 to 150 mg/day (20.4 +/- 3.4 hours; t = 2.9, p = .01).",Sertraline pharmacokinetics and dynamics in adolescents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12218424/),h,20.4,207902,DB01104,Sertraline
,19172438,peak concentrations in plasma (C(max)),"Grapefruit juice increased the mean peak concentrations in plasma (C(max)) of sertraline from 17.6+/-6.1 to 29.3+/-11.5 ng/ml (mean+/-SD, P=0.003) and the mean area under the plasma sertraline concentration-time curve (AUC) from 0 to infinity of sertraline from 402.0+/-151.9 to 820.5+/-313.0 h ng/ml (mean+/-SD, P=0.002).",Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19172438/),[ng] / [ml],17.6,209763,DB01104,Sertraline
,19172438,peak concentrations in plasma (C(max)),"Grapefruit juice increased the mean peak concentrations in plasma (C(max)) of sertraline from 17.6+/-6.1 to 29.3+/-11.5 ng/ml (mean+/-SD, P=0.003) and the mean area under the plasma sertraline concentration-time curve (AUC) from 0 to infinity of sertraline from 402.0+/-151.9 to 820.5+/-313.0 h ng/ml (mean+/-SD, P=0.002).",Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19172438/),[ng] / [ml],29.3,209764,DB01104,Sertraline
,19172438,area under the plasma sertraline concentration-time curve (AUC) from 0 to infinity,"Grapefruit juice increased the mean peak concentrations in plasma (C(max)) of sertraline from 17.6+/-6.1 to 29.3+/-11.5 ng/ml (mean+/-SD, P=0.003) and the mean area under the plasma sertraline concentration-time curve (AUC) from 0 to infinity of sertraline from 402.0+/-151.9 to 820.5+/-313.0 h ng/ml (mean+/-SD, P=0.002).",Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19172438/),[h·ng] / [ml],402.0,209765,DB01104,Sertraline
,19172438,area under the plasma sertraline concentration-time curve (AUC) from 0 to infinity,"Grapefruit juice increased the mean peak concentrations in plasma (C(max)) of sertraline from 17.6+/-6.1 to 29.3+/-11.5 ng/ml (mean+/-SD, P=0.003) and the mean area under the plasma sertraline concentration-time curve (AUC) from 0 to infinity of sertraline from 402.0+/-151.9 to 820.5+/-313.0 h ng/ml (mean+/-SD, P=0.002).",Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19172438/),[h·ng] / [ml],820.5,209766,DB01104,Sertraline
,23318280,serum concentrations,"When analyzing just the patients with depression, those with side effects had significantly higher sertraline serum concentrations than those without (44.8 ng/mL versus 22.3 ng/mL, P = 0.01).","The relation between dosage, serum concentrations, and clinical outcome in children and adolescents treated with sertraline: a naturalistic study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23318280/),[ng] / [ml],44.8,209896,DB01104,Sertraline
,23318280,serum concentrations,"When analyzing just the patients with depression, those with side effects had significantly higher sertraline serum concentrations than those without (44.8 ng/mL versus 22.3 ng/mL, P = 0.01).","The relation between dosage, serum concentrations, and clinical outcome in children and adolescents treated with sertraline: a naturalistic study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23318280/),[ng] / [ml],22.3,209897,DB01104,Sertraline
,10984808,clearance,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [h·kg],0.407,223254,DB01104,Sertraline
,10984808,volume of distribution,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [kg],4.0,223255,DB01104,Sertraline
,10984808,bioavailability,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),%,31,223256,DB01104,Sertraline
,10984808,half-life,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),h,10.6,223257,DB01104,Sertraline
,25155462,lag time,A one compartment model with lag time of 1 h and first order input and elimination adequately described the data.,The pharmacokinetics of sertraline in overdose and the effect of activated charcoal. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25155462/),h,1,232673,DB01104,Sertraline
,25155462,absorption rate constant,"The population PK parameter estimates for absorption rate constant, volume of distribution and clearance were 0.895 h(-1) , 5340 l and 130 l h(-1) , respectively.",The pharmacokinetics of sertraline in overdose and the effect of activated charcoal. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25155462/),1/[h],0.895,232674,DB01104,Sertraline
,25155462,volume of distribution,"The population PK parameter estimates for absorption rate constant, volume of distribution and clearance were 0.895 h(-1) , 5340 l and 130 l h(-1) , respectively.",The pharmacokinetics of sertraline in overdose and the effect of activated charcoal. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25155462/),l,5340,232675,DB01104,Sertraline
,25155462,volume of distribution,"The population PK parameter estimates for absorption rate constant, volume of distribution and clearance were 0.895 h(-1) , 5340 l and 130 l h(-1) , respectively.",The pharmacokinetics of sertraline in overdose and the effect of activated charcoal. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25155462/),[l] / [h],130,232676,DB01104,Sertraline
,25155462,clearance,"The population PK parameter estimates for absorption rate constant, volume of distribution and clearance were 0.895 h(-1) , 5340 l and 130 l h(-1) , respectively.",The pharmacokinetics of sertraline in overdose and the effect of activated charcoal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25155462/),[l] / [h],130,232677,DB01104,Sertraline
,25155462,half-life,The calculated half-life of sertraline following overdose was 28 h (IQR 19.4-30.6h).,The pharmacokinetics of sertraline in overdose and the effect of activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25155462/),h,28,232678,DB01104,Sertraline
,21223631,Recoveries,"Recoveries of sertraline at low, medium, and high levels were 88.0 ± 2.3%, 88.2 ± 1.9%, and 90.0 ± 2.0%, respectively.",Development and validation of an improved method for the quantitation of sertraline in human plasma using LC-MS-MS and its application to bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21223631/),%,88.0,251220,DB01104,Sertraline
,21223631,Recoveries,"Recoveries of sertraline at low, medium, and high levels were 88.0 ± 2.3%, 88.2 ± 1.9%, and 90.0 ± 2.0%, respectively.",Development and validation of an improved method for the quantitation of sertraline in human plasma using LC-MS-MS and its application to bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21223631/),%,88.2,251221,DB01104,Sertraline
,21223631,Recoveries,"Recoveries of sertraline at low, medium, and high levels were 88.0 ± 2.3%, 88.2 ± 1.9%, and 90.0 ± 2.0%, respectively.",Development and validation of an improved method for the quantitation of sertraline in human plasma using LC-MS-MS and its application to bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21223631/),%,90.0,251222,DB01104,Sertraline
,1949975,plasma elimination half-life,"Sertraline follows first-order kinetics, with a plasma elimination half-life of 24-26 hours.",Sertraline: a new specific serotonin reuptake blocker. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1949975/),h,24-26,254299,DB01104,Sertraline
,33677821,absorption rate constant (Ka),"Typical estimates for the absorption rate constant (Ka), apparent clearance (CL/F), and apparent distribution volume (V/F) were 0.30 h-1, 12.88 L/h, and 754.41 L, respectively.","The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33677821/),1/[h],0.30,265598,DB01104,Sertraline
,33677821,apparent clearance (CL/F),"Typical estimates for the absorption rate constant (Ka), apparent clearance (CL/F), and apparent distribution volume (V/F) were 0.30 h-1, 12.88 L/h, and 754.41 L, respectively.","The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33677821/),[l] / [h],12.88,265599,DB01104,Sertraline
,33677821,apparent distribution volume (V/F),"Typical estimates for the absorption rate constant (Ka), apparent clearance (CL/F), and apparent distribution volume (V/F) were 0.30 h-1, 12.88 L/h, and 754.41 L, respectively.","The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33677821/),l,754.41,265600,DB01104,Sertraline
,1281075,elimination half-life,Its elimination half-life (approximately 26 hours) makes it suitable for once daily administration.,"Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281075/),h,26,267086,DB01104,Sertraline
,8617708,trough plasma phenytoin concentrations,Concurrent treatment with sertraline (16 subjects) or placebo (13 subjects) was initiated on Day 8 and continued throughout the study in those subjects whose trough plasma phenytoin concentrations were between 5 and 20 micrograms/mL.,Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8617708/),[μg] / [ml],5 and 20,267713,DB01104,Sertraline
,10653204,apparent oral clearance,"Clonazepam apparent oral clearance, volume of distribution, and half-life were 3.9 +/- 0.2 L/hr, 233 +/-11 L, and 40.5 +/- 0.3 hours, respectively.",Clonazepam and sertraline: absence of drug interaction in a multiple-dose study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653204/),[l] / [h],3.9,269773,DB01104,Sertraline
,10653204,volume of distribution,"Clonazepam apparent oral clearance, volume of distribution, and half-life were 3.9 +/- 0.2 L/hr, 233 +/-11 L, and 40.5 +/- 0.3 hours, respectively.",Clonazepam and sertraline: absence of drug interaction in a multiple-dose study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653204/),l,233,269774,DB01104,Sertraline
,10653204,half-life,"Clonazepam apparent oral clearance, volume of distribution, and half-life were 3.9 +/- 0.2 L/hr, 233 +/-11 L, and 40.5 +/- 0.3 hours, respectively.",Clonazepam and sertraline: absence of drug interaction in a multiple-dose study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653204/),h,40.5,269775,DB01104,Sertraline
,8529300,elimination half-life,"The elimination half-life was 42-92 h (normally 24-36 h), suggesting impaired clearance.",Hemodialyzability of sertraline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529300/),h,42-92,270109,DB01104,Sertraline
,7963446,elimination half-life (t1/2),"Sertraline, and the starting dose of paroxetine have an elimination half-life (t1/2) of approximately 24 h.","Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7963446/),h,24,270767,DB01104,Sertraline
,7963446,t1/2,At t1/2 of 24 h makes once-daily dosing feasible and allows for new steady-state concentrations and wash-out within a reasonable time after dose adjustment.,"Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7963446/),h,24,270768,DB01104,Sertraline
,7963446,t1/2,Fluoxetine has a t1/2 of 2-4 days and has an active metabolite with a t1/2 of 7-15 days.,"Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7963446/),d,2-4,270769,DB01104,Sertraline
,7963446,t1/2,Fluoxetine has a t1/2 of 2-4 days and has an active metabolite with a t1/2 of 7-15 days.,"Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7963446/),d,7-15,270770,DB01104,Sertraline
